Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase
- 1 November 2014
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 86 (2) , 237-240
Abstract
No abstract availableKeywords
Funding Information
- Merck & Co., Inc.
This publication has 16 references indexed in Scilit:
- Extent and Patterns ofMGMTPromoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived SpheresClinical Cancer Research, 2011
- ABT-888 Confers BroadIn vivoActivity in Combination with Temozolomide in Diverse TumorsClinical Cancer Research, 2009
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT ActivityJournal of Clinical Oncology, 2008
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary GliomasClinical Cancer Research, 2004
- Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancerOncogene, 2004
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000